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Abstract
As a member of the thrombospondin gene family, cartilage
oligomeric protein (COMP) is found mainly in the extracellular
matrix often associated with cartilage tissue. COMP exhibits a
wide binding repertoire and has been shown to be involved in
the regulation of chondrogenesis in vitro. Not much is known
about the role of COMP in human cartilage tissue in vivo. With
the help of immunohistochemistry, Western blot, in situ
hybridization, and real-time reverse transcription-polymerase
chain reaction, we aimed to elucidate the role of COMP in
human embryonic, adult healthy, and osteoarthritis (OA)
cartilage tissue. COMP is present during the earliest stages of
human limb maturation and is later found in regions where the
joints develop. In healthy and diseased cartilage tissue, COMP
is secreted by the chondrocytes and is often associated with the
collagen fibers. In late stages of OA, five times the COMP
mRNA is produced by chondrocytes found in an area adjacent
to the main defect than in an area with macroscopically normal
appearance. The results indicate that COMP might be involved
in human limb development, is upregulated in OA, and due to its
wide binding repertoire, could play a role in the pathogenesis of
OA as a factor secreted by chondrocytes to ameliorate the
matrix breakdown.
Introduction
Cartilage oligomeric protein (COMP) is a protein of the extra-
cellular matrix and can be found in human articular cartilage
[1], meniscus [2], and cruciate ligament and tendon [3]. Lower
concentrations of COMP can also be detected in hyaline car-
tilage of the human rib and trachea [4]. It has also been
extracted from animal skeletal tissues, such as bovine tendon
and mouse, rat, and porcine cartilage [5]. COMP is an anionic,
approximately 550-kDa disulfide-linked pentameric glycopro-
tein and, as a member of the thrombospondin gene family, is
also called thrombospondin 5 [6]. Epidermal growth factor-like
and calcium-binding repeats are located in the central region
of the protein [7]. The function of COMP is still not completely
understood, but it binds to chondrocytes in vitro [8]. COMP
has been shown to bind to matrilins [9] and collagen types I,
II, and IX [10,11]. In contrast, COMP has no affinity to the
other members of the thrombospondin family [12]. The DNA-
binding protein SP1 regulates COMP expression [13] and
also mechanical compression of chondrocytes [14]. COMP
expression has been shown to be inhibited by leukemia/lym-
phoma-related factor (LRF) [15]. The human COMP gene is
located on chromosome 19 [7]. Mutations of this gene can
cause pseudoachondroplasia and multiple epiphysial dyspla-
sia [16-18]. Furthermore, COMP has been shown to be upreg-
ulated after traumatic knee injury [19] and has been implicated
in the pathogenesis of rheumatoid arthritis [20] and osteoar-
thritis (OA) [12,21]. During mouse development, COMP stain-
ing has been described around maturing articular
chondrocytes [22], and during rat development it has been
associated mainly with the growth plate [23]. Fang and col-
leagues [24] detected COMP as early as day 10 in murine
development in the condensing mesenchyme, and later it was
found in the growth plate and superficially in the developing
joint cartilage. At the time of birth, COMP has been detected
in the perichondrium, the periosteum, and the hypertrophic
zone of mouse cartilage. This, as well as in vitro experimental
evidence [25], has suggested that COMP is indispensable for
cartilage development, but in contrast COMP knockout mice
AER = apical ectodermal ridge; COMP = cartilage oligomeric protein; DIG = digoxigenin; FBI-1 = factor binding inducer of short transcripts protein-
1; gw = gestational week; IgG = immunoglobulin G; LRF = leukemia/lymphoma-related factor; OA = osteoarthritis; PBS = phosphate-buffered saline; 
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do not show an obvious skeletal phenotype [26]. There are no
published results on the role of COMP during human embry-
onic development. A single 21-week-old human foetus has
been investigated for COMP [27]. We therefore aimed to
localize COMP during embryonic human limb development,
describe it in adult healthy articular cartilage, and then com-
pare its occurrence in healthy cartilage with that of diseased
cartilage from late stages of OA.
Materials and methods
Sources of tissues
Aborted human embryos were obtained according to the reg-
ulations of the Ethics Committee of the Medical Faculty of the
University of Göttingen, Germany. The embryos were classi-
fied as follows: three embryos of gestational week (gw) 8,
three embryos of gw 10, and three embryos of gw 12. The
ages were determined from histological data according to
Carnegie stages [28]. No malformations or anomalies were
observed in these specimens.
Adult human articular cartilage from the knee joint was
obtained from 12 patients (ages 55–75) with OA who were
undergoing total knee replacement operations. The patients
met the American College of Rheumatology classification cri-
teria for OA of the knee [29]. All patients gave their written
informed consent according to the Ethics Regulations of the
Medical Faculty of the Georg-August-University Göttingen.
Four healthy control cartilage samples from accident victims
(ages 31–50) were also investigated.
Fixation and preparation of tissues
The abortion material and the cartilage specimens were trans-
ported to the laboratory in histidine-tryptophane-ketoglutarate
solution at 4°C to ensure good preservation of the tissues
[30]. The samples were fixed in 4% paraformaldehyde in phos-
phate-buffered saline (PBS), pH 7.4, at 4°C overnight. Bone-
containing samples were decalcified with buffered EDTA for
14 days. For light microscopy, specimens were dehydrated,
embedded in paraffin wax, and cut with a Reichert's micro-
tome. For the staging of the embryos, every fifth section was
stained with hematoxylin and eosin. Longitudinal sections of
the cartilage specimens stained with Alcian blue were classi-
fied as stage IV according to the OA grades (I – IV) proposed
by Collins and McElligott [31] in the case of the 12 patients
and classified as age-dependent healthy in the case of the
control cartilage samples. None of the cartilage specimens
showed any signs of rheumatoid involvement or exhibited any
osteophytes. From the 12 patients, cartilage samples from the
deep cartilage zones near the tidemark were obtained from
two different regions of the OA knee joints. One sample, with
a macroscopically normal appearance, was taken from the lat-
eral aspect of a condyle. The other one was taken from the
area adjacent to the main defect at a maximum of 0.5 cm away.
All cartilage specimens were also processed for ultrastructural
analysis. Samples (1 mm3) were embedded in LR-Gold® (Lon-
don Resin Company, Berkshire, England) according to stand-
ard procedures, and ultra-thin sections were cut with a
Reichert's ultramicrotome and collected on nickel grids
coated with Formvar® (Serva, Heidelberg, Germany).
Sources of antibodies
The anti-COMP antibody is a polyclonal rabbit-anti-bovine
antibody that has been affinity-purified [1]. Affinity-purified
sheep-anti-digoxigenin (DIG) antibodies were purchased from
Quartett (Berlin, Germany), an anti-DIG peroxidase labeled
antibody from Dakopats (Hamburg, Germany), and the sec-
ondary antibodies from Medac (Hamburg, Germany).
Samples for immunoblotting and electrophoresis
Healthy cartilage and OA cartilage samples from the area adja-
cent to the main defect were pulverized. Proteins were
extracted using 5 M guanidine hydrochloride and protease
inhibitors NEM (N-ethylmaleimide), EDTA, benzamidine hydro-
chloride, and amino caproic acid, precipitated in ethanol,
washed in PBS, precipitated again, and finally dissolved in
PBS containing 0.4% SDS. All experiments were carried out
under reducing and denaturing conditions. Protein separation
was performed applying SDS-PAGE and using systems con-
taining 6% acrylamide in stacking gels and 12% in the sepa-
ration gel. Tris-glycine was applied as electrophoresis buffer,
and separation was carried out at 100–120 V.
Western blot
After the electrophoresis, the proteins were blotted onto nitro-
cellulose membranes. Transfer was controlled by Ponceau S
staining. Thereafter, membranes were washed until no color
was left and then blocked overnight in PBS + 10% (w/v) milk
powder at room temperature. Immunoreactions were per-
formed applying the anti-COMP antibody for 2 hours, diluted
1:100 in PBS. The secondary goat-anti-rabbit antibody cou-
pled to alkaline phosphatase was diluted 1:500 and incubated
for 1 hour at room temperature. Three 5-minute washes with
PBS were carried out between all incubation steps. Visualiza-
tion was achieved using NBT/BCIP (nitrobluetetrazoline chlo-
ride/5-bromo-4-chloro-3-indolyl toluidine) coloring agent
(Roche, Heidelberg, Germany).
Light microscopic immunohistochemistry
Immunoperoxidase staining was performed on paraffin-
embedded tissue sections as follows: The tissues were depar-
affinized, rehydrated, and rinsed for 10 minutes in PBS.
Endogenous peroxidase was inhibited by a 45-minute treat-
ment with a solution of methanol and 3% H202 in the dark.
Each of the reactions was followed by rinsing for 10 minutes
in PBS. The sections were pre-treated for 5 minutes with 10
µg/ml protease XXIV (Sigma, Deisenhofen, Germany). The
anti-COMP antibody was applied at a dilution of 1:100 in PBS
for 1 hour at room temperature. A standard peroxidase-anti-
peroxidase procedure followed, applying a peroxidase-cou-
pled goat-anti-rabbit antibody (Dako, Hamburg, Germany) at aAvailable online http://arthritis-research.com/content/8/3/R56
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dilution of 1:150 in PBS for 1 hour at room temperature. The
color reaction was carried out with DAB (diaminobenzidine)
substrate (Sigma).
Controls
As negative controls, each immunoreaction was accompanied
by a reaction omitting the primary antibodies and applying rab-
bit serum diluted 1:100 in PBS instead. All controls proved to
be negative.
Immunogold histochemistry
As secondary antibody, an anti-rabbit immunoglobulin G (IgG)
(Medac) was labeled with gold particles according to standard
procedures. Ultrathin tissue sections were incubated with the
anti-COMP antibodies diluted 1:100 in PBS for 16 hours at
room temperature. The secondary gold-coupled antibodies,
diluted 1:300 in PBS, were applied for 20 minutes at room
temperature. Staining with uranyl acetate followed, and reac-
tions were examined with the help of a Zeiss EM Leo 906E
electron microscope (Carl Zeiss, Jena, Germany).
Controls
The grids were incubated with pure gold solution in order to
exclude unspecific binding of free colloidal gold. Furthermore,
the reactions were performed with gold-coupled goat-anti-
rabbit IgG, omitting the primary antibody to exclude non-spe-
cific IgG binding.
Probe preparation
RNA was isolated as described below and reverse-tran-
scribed into COMP-specific cDNA. Polymerase chain reaction
(PCR) was performed with primers specific for COMP (for-
ward AGGGAGATCGTG CAGACAA and reverse AGCT-
GGAGCTGTCCTGGTAG) to generate a 154 bp product.
They were designed with the help of the primer3shareware
[32]. Corresponding primers with the appropriate SP6/T7
promoter sequences were applied. In vitro transcription of
non-radioactive sense and antisense RNAs with a DIG labe-
ling kit (Boehringer DIG-RNA labeling kit, Boehringer, Man-
nheim, Germany) was performed applying SP6- and T7-
polymerases (Gibco/BRL, Heidelberg, Germany). After extrac-
tion of the probes with phenol-chloroform, these were precip-
itated with absolute ethanol and the pellet was dissolved in
DEPC-H2O (diethyl-pyrocarbonate).
Light and electron microscopic in situ hybridization
For light microscopic investigations, paraffin sections were
deparaffinized, rehydrated, and pre-treated with proteinase K.
The probe concentration was 100 ng of DIG-labeled anti-
sense probes in 100 µl hybridization solution (50% forma-
mide, 5 × SSC, 1 µg/µl yeast-RNA, 10 ng/µl probe) for each
section. Hybridization was carried out for 18 hours at 45°C.
Posthybridization treatment included a washing procedure
with 2 × SSC (3 × 5 minutes, at 50°C), 1 × SSC (1 × 5 min-
utes, at 60°C), 0.1 × SSC (1 × 15 minutes, at 60°C) and 0.05
× SSC (1 × 15 minutes, at 60°C). Afterward, the incubation
with the anti-DIG peroxidase-labeled antibody diluted 1:300 in
PBS was started. Finally, color reactions were started with
AEC (3-amino-9-ethylcarbazol) substrate. For electron micro-
scopy, nickel grids were incubated for 19 hours at 50°C with
the same hybridization solution as described above. The probe
concentration was 100 ng of DIG-labeled antisense probes in
20 µl hybridization solution per grid. Rinsing steps were the
same as described above. Afterward, sections were incubated
with a gold-coupled anti-DIG antibody in PBS (diluted 1:60)
for 1 hour at room temperature. The specimens were rinsed
with PBS, contrasted, and analyzed with the Zeiss EM Leo
906E.
Controls
Each of the hybridizations was accompanied by one with an
equivalently labeled amount of sense probe. Furthermore,
hybridizations were performed without any RNA probes. Addi-
tionally, for the ultrastructural controls, tissue sections were
treated with pure gold solution or the coupled anti-DIG anti-
body alone.
Statistical analysis
For in situ hybridization at the ultrastructural level, randomly
chosen micrographs of cartilage tissue with a normal appear-
ance which were taken from the lateral aspects of a condyle
and tissue samples taken from the area adjacent to the main
defect from OA cartilage (n = 10) were pooled and counted
for gold particle contents. Mean values of the numbers of gold
particles per cell were analyzed in the area of 5,000 nm2 in 10
cells from each patient. Significant differences in the number
of gold particles were noted for p values (p ≤ 0.01), using the
Wilcoxon-Mann-Whitney test for unpaired samples.
RNA extraction and real-time RT-PCR
Pieces (2 mm thick) of OA cartilage tissue taken from the area
adjacent to the main defect and pieces of tissue with a macro-
scopically normal appearance of the lateral aspect of a con-
dyle from each of the 12 patients were minced, and RNA was
isolated according to a protocol combining Trizol® and RNe-
asy kit (RNeasy® Mini Kit, Qiagen, Hilden, Germany), following
the manufacturer's instructions, and then treated with DNA-
free® (Ambion, Austin, TX, USA). The quality of the RNA was
tested with an Agilent 2100 Bioanalyser RNA chip (Agilent,
Böblingen, Germany). The RNA was reverse-transcribed with
the help of the Advantage® RT-for-PCR kit (BD Biosciences,
San Diego, CA, USA) by applying Moloney Murine Leukemia
Virus reverse transcriptase and oligo-(dT)18-primer.
PCR conditions were optimized by applying the gradient func-
tion of the DNA engine Opticon™ 2 (Bio-rad, München, Ger-
many) for HPRT-1 (NM_000194) as housekeeping gene and
for COMP. The PCR was performed in a total volume of 50 µl
with 150 ng cDNA, 5 µl 10× reaction buffer, dNTP 10 µmol
each, 20 pmol of each primer, and 2.5 U HotStarTaq® DNAArthritis Research & Therapy    Vol 8 No 3    Koelling et al.
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polymerase (Qiagen) with the DNA engine Opticon™ 2. After
an initial activation step of 15 minutes at 95°C, further steps
were as follows: 35 cycles of denaturing 30 seconds at 94°C,
annealing 30 seconds at 61°C, elongation for 30 seconds at
72°C, and (lastly) extension of 10 minutes at 72°C. Ten micro-
litres of each sample were loaded onto a 1.5% agarose gel
and were visualized by ethidium bromide after electrophoresis.
To optimize the real-time reverse transcription (RT)-PCR con-
ditions for quantification, the optimal MgCl2 concentration was
determined. Twelve point five microlitres of 2xQuantiTect™
SYBR® Green PCR Master Mix (Qiagen), 20 pmol of each
primer, and 250 ng of cDNA were added to a final volume of
25 µl. Cycling was performed with the protocol described
above. Data acquisition was carried out after each extension
step, and a melting curve was performed in 0.1°C steps from
50°–95°C. Real-time RT-PCR efficiencies were calculated
from the given slopes in Opticon™ 2 Monitor software. Real-
time RT-PCR efficiency rates were high (values of 2.00).
Experiments were performed three times in triplicate, the inter-
test variation was ≤ 2%, and the intra-test variation ≤ 1%.
Results
Light microscopic localization of COMP during human 
embryonic limb development
During human embryonic development from gw 8 to gw 12,
basement membrane zones of the developing skin stained
positive for COMP whereas the mesenchyme remained
unstained (Figure 1a). In limb buds, staining for COMP was
found in the basement membrane zone of the apical ectoder-
mal ridge (AER), and the condensed mesenchyme was not
stained (Figure 1b). During further development of the long
bones at gw 10, staining for COMP was seen throughout the
extracellular matrix of the cartilage (Figure 1c). Later, at gw 12,
staining for COMP became restricted to the margins of the
developing epiphysis (Figure 1d), the developing joint surface
(Figure 1e), and the diaphysis of long bones. COMP was seen
mostly pericellularly around hypertrophic chondrocytes along
the edges of the shaft of the diaphysis (Figure 1f).
Western blot and localization of COMP and its mRNA in 
healthy and OA human cartilage
The anti-COMP antibody [1] cross-reacted with human
COMP from healthy (Figure 2, lane 3) and OA cartilage tissue
extracts taken from the area adjacent to the main defect (Fig-
Figure 1
Light microscopic localization of cartilage oligomeric protein (COMP)  during early human bone and joint development Light microscopic localization of cartilage oligomeric protein (COMP) 
during early human bone and joint development. (a) The basement 
membrane zone of the dermal-epidermal junction is positive in a human 
embryo at (gestational week) gw 8 (arrows); the loose mesenchyme is 
not stained. (b) The same is true for the apical ectodermal ridge (AER), 
the starting point of limb development. Also, the condensed mesen-
chyme at this developmental stage is not stained. (c) At gw 10, the 
matrix of developing bones is positive for COMP. (d) Later, at gw 12, 
during joint development, COMP staining is restricted to the outer mar-
gins of the developing epiphysis (arrows), whereas the developing 
acetabulum shows still less staining (asterisks). (e) Pronounced stain-
ing for COMP (arrows) is seen adjacent to the developing joint space. 
The arrowhead indicates the area from which the high-magnification 
micrograph was taken (inset). The arrowhead in the inset indicates 
COMP staining. (f) At gw 12, COMP staining is found in the outer 
regions of the diaphysis and is mainly pericellular (inset). Bars = 70 µm 
in (f), as for (a)-(e), and 40 µm in inset (f), as for inset (e).
Figure 2
Western blot Western blot. (a) Coomassie blue staining of the tissue extract of oste-
oarthritic cartilage taken from the area adjacent to the main defect, (b) 
clear bands at 105 kDa for cartilage oligomeric protein (COMP) 
(arrow) and a fainter band at 160 kDa in the same extract, (c) a clear 
band at 105 kDa, and a smear seen for healthy articular cartilage and 
(d) shows the molecular weight marker.Available online http://arthritis-research.com/content/8/3/R56
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ure 2, lane 2). The 105 kDa band for a monomer was seen in
both extracts, whereas a second band was found only in the
OA cartilage sample and might represent a covalently bound
binding partner of COMP (for example, one of the matrilins).
This phenomenon has been observed with COMP in other
instances. The smear in the blot of healthy cartilage tissue (Fig-
ure 2, lane 3) probably results from the high aggrecan content,
which is missing in OA tissue. This is why this smear is not
found in Figure 2, lane 2, where aggrecan is lost (M. Paulsson,
personal communication). With the help of light microscopic
immunohistochemistry, COMP was localized in healthy knee
joint cartilage tissues in the pericellular, territorial, and interter-
ritorial matrix compartments. This was seen in the superficial
and middle zone. In contrast, in the deep zone near the tide-
mark, COMP was found only in the pericellular space (Figure
3a and inset). In OA cartilage, in the area adjacent to the main
defect, pronounced staining for COMP was seen (Figure 3b),
especially in the pericellular matrix of cell clusters (Figure 3b,
inset). With the help of light microscopic in situ hybridization,
the mRNA for COMP was detected in the cytoplasm of
chondrocytes of the superficial and middle zones of healthy
cartilage tissue (data not shown) and also in chondrocytes
Figure 3
Light microscopic detection of cartilage oligomeric protein (COMP)  and its mRNA Light microscopic detection of cartilage oligomeric protein (COMP) 
and its mRNA. (a) Staining for COMP is seen in the interterritorial 
matrix of the superficial and middle zones of healthy cartilage, whereas 
in the deeper zones a more pericellular pattern is found (arrow and 
inset). (b) In osteoarthritic (OA) cartilage of late disease stages, stain-
ing is seen mainly in clusters (arrow and inset). (c) In situ hybridization 
of COMP mRNA localizes it mainly in the cytoplasm of chondrocytes 
found in clusters of OA tissue (arrows); inset depicts a negative control 
of healthy cartilage. Bars, 70 µm in (a), (b), and inset (c) and 40 µm in 
(c) and insets (a) and (b).
Figure 4
Immunogold histochemistry for cartilage oligomeric protein (COMP) of  healthy and osteoarthritic (OA) tissue taken from the area adjacent to  the main defect Immunogold histochemistry for cartilage oligomeric protein (COMP) of 
healthy and osteoarthritic (OA) tissue taken from the area adjacent to 
the main defect. (a) Healthy cartilage tissue with staining for COMP in 
the pericellular space (arrow) and in the territorial matrix (asterisk). (b) 
The pericellular space of a type 2 cell of OA tissue taken from the area 
adjacent to the main defect; note the stronger staining compared with 
the healthy tissue (arrows). (c) Higher magnification of the interterrito-
rial matrix from healthy cartilage tissue; note the sparse COMP staining 
on fibers (arrow). Inset shows higher magnification of the interterritorial 
matrix taken from the area adjacent to the main defect; note the 
stronger staining for COMP on fibers (arrows). Bars, 0.4 µm in (a) and 
(b) and 0.2 µm in (c) and inset.Arthritis Research & Therapy    Vol 8 No 3    Koelling et al.
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mainly found in clusters in the area adjacent to the main defect
in OA cartilage (Figure 3c).
Immunohistochemistry of COMP in healthy and OA 
cartilage at the ultrastructural level
To elucidate which components in the differing matrix com-
partments stain for COMP, an ultrastructural analysis was per-
formed. In healthy cartilage specimens, COMP was
associated mainly with the fine fibrillar structures in the pericel-
lular space (Figure 4a). In OA cartilage taken from the area
adjacent to the main defect from patients in the late stages of
OA, an increase in staining intensity was found in the pericel-
lular space (Figure 4b). In healthy cartilage, COMP staining
was also found in the territorial and interterritorial matrix (Fig-
ure 4c), whereas in OA cartilage specimens, staining for
COMP was seen mainly on fibers but also next to them (Figure
4c, inset).
Ultrastructural in situ hybridization of COMP mRNA in 
OA cartilage
From earlier investigations on the pathogenesis of OA, we are
aware of two different cell types found in the late stages of the
disease [33,34]. Type 1 cells are the diseased chondrocytes
found in regions with a macroscopically normal appearance of
the OA cartilage, and type 2 cells are elongated, fibroblast-like
cells found mainly in the area adjacent to the main defect. A
small number of type 2 cells can also be found in the regions
with a macroscopically normal appearance in OA cartilage and
vice versa: a few type 1 cells are also present in the area adja-
cent to the main defect. To elucidate which cells, type 1 or
type 2, produce COMP mRNA, we performed in situ hybridi-
zation at the electron microscopic level. In cartilage tissue with
a normal appearance from the lateral aspects of a condyle of
the OA patients, COMP mRNA was detected in type 2 cells
(Figure 5a and inset) and less staining was seen in type 1 cells
(Figure 5b,c). In contrast, in tissue samples from the area adja-
cent to the main defect of OA cartilage of late stages of the
disease, strong staining for COMP mRNA was detected in the
cytoplasm of type 2 cells (Figure 6a) and type 1 cells (Figure
6b,c).
The number of gold particles detected in the samples with a
macroscopically normal appearance from OA tissue revealed
staining intensities of approximately 42 (SEM = 3.4) in type 1
cells and 66 (SEM = 4.1) in type 2 cells. This represents a sig-
nificant difference (p ≤ 0.01). In contrast, in both cell types
found in the areas adjacent to the main defect of OA tissue,
approximately 320 gold particles (SEM = 13.4) were detected
(Figure 7). This represents a statistically significant (p ≤ 0.01),
approximately 83% difference in staining intensity for the cells
taken from the two areas.
Figure 5
Ultrastructural in situ hybridization for cartilage oligomeric protein  (COMP) mRNA in samples taken from the area with macroscopically  normal appearance of osteoarthritic tissue Ultrastructural in situ hybridization for cartilage oligomeric protein 
(COMP) mRNA in samples taken from the area with macroscopically 
normal appearance of osteoarthritic tissue. (a) A type 2 cell is depicted 
with staining for COMP mRNA (arrows); inset shows a higher magnifi-
cation. (b) Staining for COMP mRNA (arrow) in a type 1 cell. (c) Note 
that the gold particles (arrow) are found only in the cytoplasm adjacent 
to the rough endoplasmic reticulum. Bars, 0.3 µm in (a) and (b) and 
0.25 µm in (c) and inset (a). n, nucleus.
Figure 6
Ultrastructural in situ hybridization for cartilage oligomeric protein  (COMP) mRNA of the area adjacent to the main defect of osteoarthritic  tissue Ultrastructural in situ hybridization for cartilage oligomeric protein 
(COMP) mRNA of the area adjacent to the main defect of osteoarthritic 
tissue. (a) Strong staining for COMP mRNA (arrows) is seen in a type 
2 cell; inset shows a higher magnification. (b) Strong staining for 
COMP mRNA (arrows) is seen in a type 1 cell. (c) Note that the gold 
particles (arrows) are found only in the cytoplasm at the rough endo-
plasmic reticulum. Bars, 0.3 µm in (a) and (b) and 0.25 µm in (c) and 
inset (a). n, nucleus.Available online http://arthritis-research.com/content/8/3/R56
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Quantitative real-time RT-PCR
To validate the semi-quantitative results from the ultrastruc-
tural in situ hybridization, we performed quantitative real-time
RT-PCR. The mean threshold cycle value for COMP cDNA
detected in tissue samples from patients with late stages of
OA taken from the area adjacent to the main defect is 16.2,
representing a relative ratio of 8.28, and the value detected in
samples of cartilage tissue with a macroscopically normal
appearance is approximately 27.5 (Figure 8a), representing a
ratio of 0.16. The relative ratios were calculated according to
the algorithm of Pfaffl. The relative ratio for COMP in normal
cartilage tissue is approximately 98% lower when compared
with OA tissue. The calibrator curve obtained by the correla-
tion of the threshold cycle values with the dilution series of the
housekeeping gene exhibited a low (≤ 1%) intra-test variation
(Figure 8b,c). The validity of the PCR results was confirmed by
sequencing and by the melting curves performed for each
PCR (data not shown).
Discussion
Until now, nothing has been known about the role of COMP
during human development. COMP has been shown to be
located in porcine joints, where high levels were seen in the
proliferating zones and low levels were seen in the hyper-
trophic zones [5], which differs from what we found for human
embryonic development. During human bone development
investigated here, the strongest staining for COMP was seen
in areas where joint development had taken place. This differs
from mouse development, in which COMP is seen mainly in
the perichondrium, but is in line with the present results, which
demonstrate COMP-positive hypertrophic cartilage zones
also during human development [27]. We were able to show
COMP-positive superficial cartilage zones, as already
described for mice [24]. Additionally, we detected COMP in
the middle zones and in deep cartilage zones near the tide-
mark. Furthermore, COMP was detected in the basement
membrane zones of the AER, the earliest signs of limb bud for-
mation, but not in the condensing mesenchyme as described
for murine development [24]. There is evidence from in vitro
models that COMP is involved in the regulation of chondro-
genesis [25]. In contrast, COMP knockout mice do not exhibit
an obvious skeletal phenotype [26]. In light of these previous
results and the localization of COMP during human limb devel-
opment in the correct spacial and time relationship presented
here, which is different from the more general distribution of
Figure 7
Statistical analysis of the ultrastructural in situ hybridization Statistical analysis of the ultrastructural in situ hybridization. The two 
bars on the left depict the mean numbers of gold particles for cartilage 
oligomeric protein (COMP) mRNA in type 1 and type 2 cells from the 
area with a macroscopically normal appearance of osteoarthritic (OA) 
tissue. The two bars on the right show the mean numbers of gold parti-
cles in the same cell types taken from the area adjacent to the main 
defect of OA cartilage.
Figure 8
Quantitative real-time reverse transcription-polymerase chain reaction  (PCR) Quantitative real-time reverse transcription-polymerase chain reaction 
(PCR). (a) Graphs for cartilage oligomeric protein (COMP) of samples 
of osteoarthritic cartilage tissue taken from the area adjacent to the 
main defect (1) and of cartilage tissue with a macroscopically normal 
appearance (2). Note that the slopes of the graphs, each color repre-
senting one PCR reaction, are highly similar. A significant difference 
between threshold cycle [C(T)] values of (1) and (2) is shown. (b) The 
decreasing C(T) values of the standard dilution of the housekeeping 
gene HPRT-1 are shown. (c) Standard curve derived from the standard 
dilution.Arthritis Research & Therapy    Vol 8 No 3    Koelling et al.
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COMP during mouse development, it can be speculated that
COMP plays a more specific role during human skeletal devel-
opment, especially in joint formation, which needs to be further
elucidated.
COMP is also present in healthy adult articular cartilage, as
demonstrated here with the help of a Western blot, as well as
in vivo at the light and electron microscopic level. Earlier,
COMP was detected in the normal growth plate of primates
[35] and was shown to bind to adult normal bovine chondro-
cytes in vitro [8]. COMP was also shown to bind to matrilins
[9], as well as to collagen types I, II, and IX [11]. This could
imply that the protein could function as one of the link mole-
cules to organize and stabilize the extracellular cartilage matrix.
Indeed, at the ultrastructural level, COMP was found to be
associated with the fibers of the pericellular, territorial, and
interterritorial space of healthy and OA human cartilage tissue
taken from the area adjacent to the main defect. Furthermore,
COMP staining was also detected next to the cells in the peri-
cellular space associated with its fine fibrillar material. There-
fore, COMP might also be involved in chondrocyte regulation,
as is already known, for example, for decorin [34].
It has been shown that high serum levels of COMP are asso-
ciated with the progression of OA [21]. Altered cell-matrix
interactions underlie the pathogenesis of OA [36], especially
for late disease stages investigated here [34]. The process of
OA seems to begin with a continuous breakdown of the matrix
framework [37] and results in a loss of matrix strength [38].
Here we found increased amounts of COMP mRNA in the
area adjacent to the main defect of OA cartilage of late dis-
ease stages, where the main regeneration efforts take place
[39,40]. The type 2 cells from this area are the only cells newly
emerging in late stages of the disease and are signs of the
regeneration processes [34,39,41]. They produce five times
more COMP mRNA than the same cells taken from the tissue
with a macroscopically normal appearance of the lateral
aspects of a condyle of OA cartilage. Furthermore, these
results were backed up by the quantitation of real-time RT-
PCR results. Dynamic loading increases the expression of
COMP, and higher COMP mRNA levels can be found two
days after compression [14]. This is in line with the present
results demonstrating the highest COMP mRNA levels in the
regions adjacent to the main defect, where the highest load
occurs. This can be taken as evidence that COMP, with its
multiple binding possibilities, might be secreted by the
chondrocytes in late stages of the disease to ameliorate the
breakdown of the extracellular matrix. An enhanced production
of matrix components at the transcriptional and translational
levels has also been demonstrated for other molecules with
known functions within the matrix framework, such as decorin
and biglycan [33] or perlecan [41], whereas the main cartilage
collagen, collagen type II, has been shown to be downregu-
lated [42].
One of the known factors of COMP gene expression regula-
tion in mice is the LRF, which inhibits COMP transcription and
decreases collagen type II expression via downregulation of
bone morphogenetic protein-2 in vitro [15]. The human
COMP gene promoter contains a typical consensus site for
binding to LRF/factor binding inducer of short transcripts pro-
tein-1 (FBI-1) [15]. If FBI-1 [43] acts as human counterpart of
murine LRF, human COMP expression should be downregu-
lated by FBI-1. As shown here, in late stages of human OA in
vivo, chondrocytes upregulate their COMP expression and, as
shown earlier, downregulate their collagen type II expression
[42]. This differs from the mouse model that indicates that
LRF/FBI-1 is the general transcription factor for the downreg-
ulation of COMP and collagen type II [15]. If LRF/FBI-1 initially
downregulates  COMP  and collagen type II in human OA,
which in turn enhances the matrix breakdown and thereby
increasing the mechanical load of the diseased tissue, this
mechanical load could counteract the LRF/FBI-1 effect and
upregulate only the COMP expression in late stages of the dis-
ease, as shown here for the areas bearing the highest load in
human OA tissue in vivo.
Conclusion
In summary, our results demonstrate that COMP is present in
the earliest stages of human bone and joint development.
COMP is also a component of the adult healthy articular carti-
lage matrix and is produced by the chondrocytes. Further-
more, we were able to show that during late stages of OA,
increased amounts of COMP are produced by type 1 and type
2 cells in the area adjacent to the main defect and that due to
its wide binding repertoire, COMP might therefore be involved
in the regeneration efforts of OA cartilage tissue as a factor
secreted by chondrocytes to ameliorate the matrix breakdown.
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